Latest news with #FutureReady
Yahoo
10-06-2025
- Business
- Yahoo
Boys & Girls Clubs joins movement to help youth become 'future ready'
The Boys & Girls Clubs of Central Carolina announced recently its official commitment to Future Ready, a strategic direction launched by Boys & Girls Clubs of America to meet the urgent needs of today's youth and shape the future of youth development nationwide. The Future Ready movement unites more than 1,000 local Boys & Girls Club organizations under a shared mission: to empower young people with the skills, experiences and support they need to thrive in school, work and life. As the challenges facing youth continue to evolve—from mental health struggles and academic disruption to economic uncertainty and the digital divide—BGCCC is stepping forward with an ambitious local plan to grow impact and deepen community leadership. Local Goals for 2028• Increase average daily attendance from 338 to 500 • Grow registered membership from 1,129 to 1,500 • Expand teen membership from 177 to 275 'Our commitment to Future Ready is more than a pledge—it's a promise to the kids and teens in our communities,' said Fallon Brewington, CEO of Boys & Girls Clubs of Central Carolina. 'We are creating spaces where young people are safe, supported and empowered to build their brightest futures.' Five Strategic Priorities• Organizational strength: BGCCC is investing in the professional development of its board and leadership team, with an emphasis on recruitment, onboarding and volunteer retention. • Talent development: Staff and volunteers will benefit from enhanced training, onboarding, and compensation strategies to strengthen our culture of excellence. • Youth & Teen Impact: BGCCC is launching new initiatives to increase teen engagement, including plans to open a Teen Workforce Development Center in Siler City by 2028. • Influence: With the recent hire of a director of resource development & marketing, BGCCC is actively working to build brand awareness and elevate youth voices in local conversations. • Digital transformation: Technology upgrades for staff and members are underway to improve the Club experience and operations across all sites. BGCCC encourages supporters, partners and community leaders to join in this transformational work. Whether through advocacy, philanthropy or volunteering, every effort helps bring our communities—and our youth—closer to being Future Ready.
Yahoo
10-06-2025
- Health
- Yahoo
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled insulin at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20-23 in Chicago. Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a 'Future Ready' symposium. Dr. Haller is the Chair for MannKind's Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). The presentation/posters planned at ADA's 85th Scientific Sessions regarding the most recent advances in inhaled insulin treatment include: Symposium – Future Ready – Breakthrough in Pediatric Type 1 Diabetes Care Sunday, June 22 – 1:30 to 3:00 p.m. (Central) in Room W 181(A-C)Dr. Michael J. Haller will present: From Discovery to Treatment – Latest Updates on Inhaled Insulin Treatment Patient Reported Outcomes with Use of Inhaled Technosphere Insulin (T1) (Board 827)Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central) Presenter: Dr. Peter Calhoun Efficacy and Safety of Prandial Technosphere Inhaled Insulin (Afrezza) Compared with Placebo in Adult Individuals with T2DM – Results from a Phase III Clinical Trial from India (Board No. 833)Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central) Presenter: Dr. K M Prasanna Kumar Additionally, MannKind will host booth #1617 in the Exhibit Hall throughout the ADA's Scientific Sessions. Members of MannKind's Medical Education Team will be available for scientific exchange in the medical section of the booth. For more information about ADA's Scientific Sessions programming, and/or to register to attend the conference, please visit: MannKind expects to issue the topline results from the full study pediatric data set with safety extension in 2Q 2025 and anticipates submitting a Supplemental Biologics License Application in mid-2025 for a potential pediatric indication for Afrezza. About MannKindMannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit to learn more, and follow us on LinkedIn, Facebook, X or Instagram. Forward-Looking StatementsThis press release contains forward-looking statements about a planned release of scientific data and a potential sBLA submission for Afrezza that involves risks and uncertainties. Words such as 'believes', 'anticipates', 'plans', 'expects', 'intends', 'will', 'goal', 'potential' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that issues that develop in the preparation of data releases and filings may subject us to unanticipated delays as well as other risks detailed in MannKind's filings with the Securities and Exchange Commission, including under the 'Risk Factors' heading of its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. AFREZZA and MANNKIND are registered trademarks of MannKind Corporation. CONTACT: MannKind Contacts: Media Relations Christie Iacangelo, (818) 292-3500 Email: media@ Investor Relations Ana Kapor, (818) 661-5000 Email: ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-06-2025
- Health
- Yahoo
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled insulin at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20-23 in Chicago. Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a 'Future Ready' symposium. Dr. Haller is the Chair for MannKind's Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). The presentation/posters planned at ADA's 85th Scientific Sessions regarding the most recent advances in inhaled insulin treatment include: Symposium – Future Ready – Breakthrough in Pediatric Type 1 Diabetes Care Sunday, June 22 – 1:30 to 3:00 p.m. (Central) in Room W 181(A-C)Dr. Michael J. Haller will present: From Discovery to Treatment – Latest Updates on Inhaled Insulin Treatment Patient Reported Outcomes with Use of Inhaled Technosphere Insulin (T1) (Board 827)Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central) Presenter: Dr. Peter Calhoun Efficacy and Safety of Prandial Technosphere Inhaled Insulin (Afrezza) Compared with Placebo in Adult Individuals with T2DM – Results from a Phase III Clinical Trial from India (Board No. 833)Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central) Presenter: Dr. K M Prasanna Kumar Additionally, MannKind will host booth #1617 in the Exhibit Hall throughout the ADA's Scientific Sessions. Members of MannKind's Medical Education Team will be available for scientific exchange in the medical section of the booth. For more information about ADA's Scientific Sessions programming, and/or to register to attend the conference, please visit: MannKind expects to issue the topline results from the full study pediatric data set with safety extension in 2Q 2025 and anticipates submitting a Supplemental Biologics License Application in mid-2025 for a potential pediatric indication for Afrezza. About MannKindMannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit to learn more, and follow us on LinkedIn, Facebook, X or Instagram. Forward-Looking StatementsThis press release contains forward-looking statements about a planned release of scientific data and a potential sBLA submission for Afrezza that involves risks and uncertainties. Words such as 'believes', 'anticipates', 'plans', 'expects', 'intends', 'will', 'goal', 'potential' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that issues that develop in the preparation of data releases and filings may subject us to unanticipated delays as well as other risks detailed in MannKind's filings with the Securities and Exchange Commission, including under the 'Risk Factors' heading of its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. AFREZZA and MANNKIND are registered trademarks of MannKind Corporation. CONTACT: MannKind Contacts: Media Relations Christie Iacangelo, (818) 292-3500 Email: media@ Investor Relations Ana Kapor, (818) 661-5000 Email: ir@ in to access your portfolio
Associated Press
09-06-2025
- Business
- Associated Press
Vallous International Launches Energy Efficiency Initiative Aligned with Singapore Green Plan 2030
SINGAPORE - Media OutReach Newswire - 9 June 2025 - Vallous International has announced the launch of its Energy Efficiency Initiative, a bold step toward building resilient, future-ready infrastructure in alignment with the Singapore Green Plan 2030. Vallous International Launches Energy Efficiency Initiative Aligned with Singapore Green Plan 2030 Transforming Infrastructure for the Future This programme targets organisations across Singapore, ranging from commercial & industrial buildings to data centres. The objective is to enhance their performance in sustainability, energy efficiency, and operational resiliency. Recognising that power resiliency is now a strategic business enabler rather than a mere technical function, Vallous International aims to address critical challenges, such as outdated systems, fragmented vendor environments, and rising sustainability demands. Many existing infrastructures fall short of today's carbon-conscious standards and are not equipped to handle modern AI workloads or grid instabilities. 'Our clients need intelligent, integrated systems that can keep operations running 24/7 while promoting energy efficiency,' said Matthew Kee, Head of Solutions & Operations at Vallous International. 'We saw a clear opportunity to support businesses with brand-agnostic, full-service infrastructure solutions that are sustainable, resilient, and future-proof.' Key Goals and Measurable Impact Vallous International adopts a continuous improvement approach—Plan, Measure, Review, Refine—to help clients achieve and exceed their energy-saving targets. The company will track the success of this initiative through these key metrics: Real-World Results and Community Impact Initial implementations have already shown results: Focusing on UPS data centres, this project marked a 12-month uptime record with a 30% reduction in energy usage and Green Mark certification. Enabled smaller enterprises to enhance critical infrastructure with reduced downtime and improved customer satisfaction scores. As these projects scale, Vallous anticipates lower energy consumption across Singapore's commercial sectors. This should be achieved without compromising business continuity or end-user experience. Stakeholder and Ecosystem Engagement Employee engagement is central to the initiative's success, with internal teams and partners encouraged to share success stories and champion sustainability goals. Vallous International also strengthens its ecosystem approach by working closely with OEMs, SMEs, and public agencies to deliver integrated, multi-vendor infrastructure solutions. 'This energy efficiency initiative is more than just a CSR exercise; it also offers a strategic advantage,' as revealed by Peggy Chng, Managing Director at Vallous International. 'Aligned with our sustainability priorities, this initiative boosts our brand reputation and deepens client trust. We would also like to thank our partners for multiplying the positive impact.' Future Outlook With this initiative, Vallous reinforces its commitment to supporting business continuity and environmental leadership. In line with the Singapore Green Plan 2030, the company looks to set a precedent for how technology and sustainability can intersect to drive meaningful, scalable change. Hashtag: #VallousInternational #SustainableInnovation #GreenPlan2030 The issuer is solely responsible for the content of this announcement. About Vallous International Pte Ltd Vallous International specialises in critical power solutions, data centre engineering, IT infrastructure, connectivity, and maintenance support. The company supports the core operations of digitally focused organisations through resilient, future-ready technology and infrastructure.
Yahoo
29-05-2025
- Business
- Yahoo
HPQ Q1 Earnings Call: Tariff Costs Pressure Margins and Guidance Cut Amid Personal Systems Growth
Personal computing and printing company HP (NYSE:HPQ) missed Wall Street's revenue expectations in Q1 CY2025 as sales rose 3.3% year on year to $13.22 billion. Its non-GAAP EPS of $0.71 per share was 11.6% below analysts' consensus estimates. Is now the time to buy HPQ? Find out in our full research report (it's free). Revenue: $13.22 billion (3.3% year-on-year growth) Adjusted EPS: $0.71 vs analyst expectations of $0.80 (11.6% miss) Management lowered its full-year Adjusted EPS guidance to $3.15 at the midpoint, a 12.5% decrease Operating Margin: 4.9%, down from 7.4% in the same quarter last year Market Capitalization: $25.64 billion HP's first quarter results reflected a mix of growth in its Personal Systems segment and ongoing operational challenges, particularly from new tariff costs. Management highlighted that commercial PC demand and the company's expansion into high-value categories were central to top-line growth. CEO Enrique Lores noted, 'We saw strong growth in personal systems, particularly in commercial and high-value categories, driving momentum in our key growth area.' However, the quarter's operating profit was negatively affected by additional tariffs that could not be fully mitigated, with management citing a roughly $0.12 per share impact on non-GAAP earnings. Lores described the external landscape as 'highly dynamic,' pointing to shifting trade policies as a primary factor behind the shortfall in profitability. Looking forward, HP's updated guidance is shaped by continued uncertainty in the global trade environment and macroeconomic conditions. Management expects the recently accelerated supply chain rebalancing and pricing actions to help restore margins by the end of the year, though they stressed that the pace of PC market recovery remains uncertain. CFO Karen Parkhill stated, 'We believe it is prudent to moderate our guidance for the second half of the year to reflect' evolving trade policy and demand trends. The company also anticipates that its ongoing Future Ready cost savings program and the growing role of AI PCs will be key contributors to performance in the coming quarters. Management attributed the quarter's top-line growth to commercial PC momentum and high-value mix shifts but emphasized that unmitigated tariffs and manufacturing adjustments weighed on margins. Commercial PC segment momentum: Personal Systems revenue growth was led by strong commercial demand, especially in North America and Asia, with notable gains in premium, workstation, and AI-enabled PCs (AIPCs). Management credited the Windows 11 refresh cycle and increased enterprise adoption for driving performance. Tariff-related cost headwinds: The introduction of new tariffs increased costs by an estimated 100 basis points on non-GAAP operating profit, mainly affecting the Personal Systems segment. Management responded by accelerating supply chain diversification, but these actions only partially offset the impact during the quarter. Manufacturing footprint diversification: HP significantly expanded production outside China, increasing output from Vietnam, Thailand, India, Mexico, and the US. By the end of June, nearly all products sold in North America are expected to be manufactured outside China, according to CEO Lores. Print division performance split: Print revenue declined as expected, with growth in Europe offset by continued weak demand in China and North America. The company emphasized gains in home printer units and the success of its 'big tank' product line, as well as growth in consumer subscriptions and industrial printing solutions. Cost control and operational agility: HP drove down non-GAAP operating expenses year-over-year through process efficiency, automation, and portfolio optimization. The company's Future Ready program is now expected to deliver at least $2 billion in annualized structural savings by year-end, supporting strategic investment despite external headwinds. Management's outlook for the next few quarters centers on mitigating tariff costs, driving AI PC adoption, and executing operational savings programs to offset macroeconomic uncertainty. Tariff mitigation and supply chain shifts: The company expects to fully offset current tariff-related costs by the end of the year through accelerated supply chain reconfiguration, targeted pricing actions, and additional cost-cutting. Management emphasized that manufacturing outside China will provide greater operational flexibility if trade policies evolve further. AI PC adoption and premium mix shift: HP anticipates that AI-enabled PCs (AIPCs) will comprise over 25% of PC shipments by year-end, boosting average selling prices and gross margins. CEO Lores stated that 'AI PCs are between 10% and 20% higher priced than regular PCs,' projecting this mix shift as a multi-year growth driver. Cost discipline and Future Ready program: The ongoing Future Ready program aims to deliver $2 billion in annualized structural savings by year-end through organizational streamlining, IT consolidation, and portfolio optimization. Management expects these savings to help maintain profitability and enable continued investment in strategic growth areas, even as industry-wide demand remains uncertain. In the coming quarters, the StockStory team will monitor (1) the pace and effectiveness of HP's supply chain transition out of China, (2) the adoption rate and pricing dynamics of AI-enabled PCs, and (3) progress toward the $2 billion annualized cost savings target under the Future Ready program. Additional factors include margin recovery in Personal Systems and Print as tariff mitigation efforts gain traction. HP currently trades at a forward P/E ratio of 7.5×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
